Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06577116 · ClinicalTrials.gov registry record · Phase 1
Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001
A Phase 1 study of Chronic Spontaneous Urticaria, sponsored by Allakos.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 14
- Study locations
NCT06577116: Completed Phase 1 study of Chronic Spontaneous Urticaria, sponsored by Allakos.
NCT06577116 is a Phase 1 study of Chronic Spontaneous Urticaria that has completed, run by Allakos. The registered enrollment target is 29 participants, below the 1,426-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (98% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06577116, a Phase 1 study of Chronic Spontaneous Urticaria, has completed, sponsored by Allakos.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 14
- Study locations
Study Summary
An open label extension (OLE) study offered to subjects with Chronic Spontaneous Urticaria that have completed the AK006-001 (NCT06072157) Part C referred to as the Main study portion of the study. Qualified subjects will receive up to four doses of the study drug (AK006) through an intravenous infusion every 4 weeks. There is a 16-week follow up period once all the scheduled infusions have been completed. Subjects will be follow for evaluation of safety, tolerability, PK, immunogenicity, and clinical response.
Conditions Studied
Interventions
- DRUG AK006 IV
Study Locations (14)
California
- Site 601-014 - Bakersfield
- Site 601-015 - Upland
Ontario
- Site 601-107 - Niagara Falls
- Site 601-108 - Toronto
Quebec
- Site 601-102 - Québec
- Site 601-105 - Québec
Alabama
- Site 601-004 - Birmingham
Kansas
- Site 601-006 - Overland Park
Kentucky
- Site 601-019 - Lexington
Missouri
- Site 601-011 - St Louis
Ohio
- Site 601-002 - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2025-05-21 |
| Phase | Phase 1 |
What the finished NCT06577116 record still lists
NCT06577116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 1,426-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Chronic Spontaneous Urticaria appearing as the primary indexed condition, and to 1 intervention - of which AK006 IV is the first listed.
NCT06577116 lists 14 locations in 11 states (California, Ontario, Quebec).
Frequently Asked Questions
What is clinical trial NCT06577116 about?
NCT06577116 is a clinical study titled "Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001". An open label extension (OLE) study offered to subjects with Chronic Spontaneous Urticaria that have completed the AK006-001 (NCT06072157) Part C referred to as the Main study portion of the study. Qualified subjects will receive up to four doses of the study drug (AK006) through an intravenous infu...
What is the current status of trial NCT06577116?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2024-08-28. Estimated completion is 2025-05-21.
What conditions does trial NCT06577116 study?
This clinical trial studies the following conditions: Chronic Spontaneous Urticaria.
What interventions are being tested in trial NCT06577116?
The interventions under investigation include: AK006 IV (DRUG).
Who is sponsoring clinical trial NCT06577116?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06577116 being conducted?
This trial has 14 study locations across Alabama, California, Kansas, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Spontaneous Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06577116's enrollment target sits among peer trials
29 18th of 18 higher than 1 of 18 other Chronic Spontaneous Urticaria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Spontaneous Urticaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
ACTIVE NOT RECRUITING · Phase 1
-
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
RECRUITING · Phase 2
-
Remibrutinib in Real-world Clinical Practice - a US Sub-study
RECRUITING
-
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
RECRUITING · Phase 2
-
Remibrutinib in Real-world Clinical Practice
RECRUITING
-
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI